Advertisement
U.S. markets open in 2 hours 6 minutes
  • S&P Futures

    5,306.00
    -2.25 (-0.04%)
     
  • Dow Futures

    40,141.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    18,493.00
    -10.75 (-0.06%)
     
  • Russell 2000 Futures

    2,138.80
    +0.40 (+0.02%)
     
  • Crude Oil

    82.40
    +1.05 (+1.29%)
     
  • Gold

    2,232.40
    +19.70 (+0.89%)
     
  • Silver

    24.75
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.98
    +0.20 (+1.56%)
     
  • dólar/libra

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.3510
    +0.1050 (+0.07%)
     
  • Bitcoin USD

    70,829.95
    +745.47 (+1.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,956.13
    +24.15 (+0.30%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Amarantus BioScience President and CEO Publishes New Blog Entitled “LymPro Heading into 2014: Shifting the Diagnostic Paradigm in Alzheimer’s”

Amarantus BioScience, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's President and CEO, Gerald E. Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus President and CEO, Gerald E. Commissiong, reflects on the changing landscape of US healthcare as the Affordable Care Act is implemented. He writes about the potential impact the "addition of new rules encouraging preventative measures" could have on the commercialization of LymPro. Read his full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/gerald-commissiong/2013-11/lympro-heading-into-2014-shifting-the-diagnostic-paradigm-in-alzheimers.html).

About Amarantus BioScience, Inc.

AmarantusBioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information, please visit http://www.amarantus.com/.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.

Advertisement